Methamphetamine (METH) is widely abused in the world. 1 Especially in Japan, the number of people arrested for METH possession or use is approximately 100 times more than those arrested for cocaine or cannabis. Further, METH frequently induces psychotic states with symptoms similar to those seen in schizophrenia of the paranoid type.
2 Such psychotic states are mainly treated in hospitals resulting in large medical costs. Thus, there is great need for the discovery of new medications for METH abuse, 3 as the current treatments are primarily oriented toward the treatment of psychosis with no treatments available to prevent relapse to METH abuse. Dopamine transporters (DAT) are the main targets for METH and cocaine. However, mice lacking the DAT show preference for cocaine 4 and self-administer cocaine. 5 Interestingly, heterozygous and homozygous serotonin transporter (SERT) knockout (KO) mice that also have a homozygous KO of the DAT do not exhibit cocaine place preference. 6 Further, findings indicated that extracellular dopamine concentration increases after cocaine administration in the striatum of DAT KO mice but not of DAT/SERT double KO mice. 7 Taken together, these reports suggest that SERT inhibition may decrease METH and cocaine place preference.
In the present study, we tested this hypothesis by assessing whether fluoxetine, a selective serotonin reuptake inhibitor (SSRI) with the trade name of Prozac, reduces METH place preference and sensitization to the locomotor activating effects of METH.
MATERIALS AND METHODS
Male C57BL/6J mice (8-10 weeks old) were purchased from CLEA Japan, Inc. (Tokyo, Japan) and were housed for 1-2 weeks before the experiments were begun in an animal facility maintained at 24 ± 1
• C and 50% relative humidity under a 12/12 h light/dark cycle with lights on at 8:00 AM and off at 8:00 PM. Food and water were available ad libitum. The experimental procedures and housing conditions were approved by the Institutional Animal Care and Use Committee of the Tokyo Institute of Psychiatry, and all animals were cared for and treated humanely in accordance with our institutional animal experimentation guidelines.
Conditioned Place Preference (CPP) Test
The conditioned place preference (CPP) test was carried out according to the method of Hoffman and Beninger 8 with some modifications. For this test, we used a two-compartment Plexiglas chamber (Neuroscience Inc., Osaka, Japan), one compartment was black with a smooth floor and the other was of the same dimensions, but white with a textured floor. This two-compartment chamber was placed in a sound-and light-attenuated box under conditions of dim illumination (about 40 lx). There was no significant difference between time spent in the black compartment and time spent in the white compartment on day 2 of testing (see below), indicating that there was no preference for either side under the present conditions before conditioning. As described previously, 9 we selected a counterbalanced protocol in order to nullify each mouse's initial compartment preference.
On day 1, the mice (n = 15∼16 per group) were allowed to freely explore the two compartments for 15 min. On day 2, again the mice were allowed to explore the two compartments freely for 15 min, and the time spent in each compartment and the number of transitions between compartments were measured. Then, conditioning sessions were conducted once daily for 4 consecutive days (days 5-8). Mice were intraperitoneally (i.p.) injected with METH (2 mg/kg) and immediately confined to the black or white compartment for 50 min on day 5. On day 6, the mice were injected with saline and immediately confined to the opposite compartment for 50 min. On days 7 and 8, the same conditioning as on days 5 and 6 was repeated. Fluoxetine (20 mg/kg i.p.) or saline was injected 60 min before METH or saline treatment. On day 9, the mice were pretreated with saline or fluoxetine (20 mg/kg). Sixty minutes later, the mice were allowed to freely explore the two compartments for 15 min without METH injection, and the time spent in each compartment and the number of transitions between compartments were measured (see FIG. 1 for a diagram of the experimental design). The CPP score was designated as the time spent The CPP score was designated as the time spent in the METH-paired compartment minus the time spent in the same compartment in the preconditioning phase. There was significant CPP in the S-S, F-S, and S-F groups, but not when fluoxetine was administered before both the conditioning phase and the CPP test phase (F-F) (within-group paired t-tests, * * * P < 0.001, * P < 0.05, NS: not significant [P > 0.05]). The CPP scores were expressed as means ± the standard error of the mean (SEM).
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in the METH-paired compartment on day 9 minus the time spent in the same compartment in the preconditioning phase on day 2.
Locomotor Activity
METH-induced locomotor activity was examined in mice (n = 15∼16 per group) injected with METH (1 mg/kg i.p.) seven times every other day, for a total of seven injections over 13 consecutive days. Mice were placed at the center of the test chamber (250 mm in diameter and 270 mm in height; Muromachi Kikai Co., Tokyo, Japan) and allowed to freely explore the chamber for 120 min. Then, fluoxetine (20 mg/kg) or saline was injected i.p. and the mice were placed in the locomotor activity chamber immediately afterwards. Sixty minutes later, METH was injected i.p. and locomotor activity was assessed for 60 min after the METH administration by using an infrared activity monitor.
Drugs
Methamphetamine hydrochloride was purchased from Dainippon Pharmaceutical (Osaka, Japan), and fluoxetine hydrochloride was purchased from Sigma (St. Louis, MO, USA). All drugs were dissolved in saline. Drugs and vehicle were administered (i.p.) in a volume of 0.1 mL/10 g of body weight.
Statistical Analyses
For the CPP data, the time that the mice spent in the METH-paired compartment before and after conditioning were compared with within-group paired t-tests for each group. The CPP scores of mice pretreated with fluoxetine or saline in the conditioning phase and CPP test phase were subjected to a twoway analysis of variance (ANOVA). Locomotor activity was subjected to a two-way mixed-design ANOVA followed by post hoc comparisons with the Scheffe test.
RESULTS

Effects of Fluoxetine on the METH CPP
Mice pretreated with saline in the conditioning phase and the CPP test phase (S-S) spent significantly longer time in the METH-paired compartment after conditioning than before conditioning (df = 14, t = −4.262, P = 0.0008) (FIG. 1) . The mice pretreated with fluoxetine (20 mg/kg) in the conditioning phase or the CPP test phase (F-S and S-F) also showed significant METH CPP (df = 14, t = −2.739, P = 0.0160; df = 14, t = −2.400, P = 0.0309, respectively), although the CPP scores were lower than that of S-S group. Mice pretreated with fluoxetine (20 mg/kg) in the conditioning phase and the CPP test phase (F-F) did not show METH-CPP (df = 14, t = −1.073, P = 0.3015). Furthermore, the two-way ANOVA revealed that fluoxetine pretreatment in the CPP test phase resulted in a trend toward a decrease of the CPP score when compared to mice treated with saline before the CPP test phase (F 1,56 = 3.857, P = 0.0545). There was no statistically significant interaction between the factors fluoxetine/saline for the conditioning phase and CPP test phase (F 1,56 < 0.0001, P = 0.9972). Fluoxetine pretreatment had no significant effects on number of transitions between the compartments (data not shown).
Effects of Fluoxetine on METH-Induced Locomotor Sensitization
Fluoxetine (20 mg/kg) or saline was injected 60 min before METH (1 mg/kg) administration every other day when METH was administered. We selected this fluoxetine dose because the number of transitions between compartments in the CPP test was not altered by this dose of fluoxetine, indicating no significant influence of fluoxetine itself on locomotor activity at this dose. Locomotor activity during the 60-min period immediately after METH administration was analyzed using a two-way mixed-design ANOVA (FIG. 2) . The administration of METH led to sensitization to the locomotor activating effects of METH as FIGURE 2. Locomotor activity after METH injection in mice pretreated with either fluoxetine or saline. Locomotor activity was measured by infrared activity counters. Locomotor activity of mice pretreated with fluoxetine was significantly lower than that of mice pretreated with saline. The locomotor activity counts were expressed as mean ± SEM * P < 0.05, * * P < 0.01.
reflected by a main effect of Day (F 6,29 = 41.542, P < 0.0001). Further, there was a main effect of fluoxetine indicating that fluoxetine inhibited locomotor activity (F 1,29 = 6.696, P = 0.0149) at this test. Finally, there was also a statistically significant interaction effect reflecting the fact that pretreatment with fluoxetine had inhibitory effects on locomotor sensitization (interaction between the factor METH and the factor pretreatment; F 6,29 = 4.851, P = 0.0001). The post hoc comparisons revealed that the locomotor activity of mice pretreated with fluoxetine was significantly lower than that of mice pretreated with saline on days 7, 11, and 13.
DISCUSSION
Fluoxetine abolished METH CPP and significantly reduced sensitization to the locomotor activating effects of METH in the present study. The abolishment of METH CPP by fluoxetine pretreatment suggests that fluoxetine reduces preference for contextual stimuli previously associated with METH, while the inhibition of sensitization to METH-induced locomotor activation by fluoxetine indicates that fluoxetine may be a useful tool for preventing sensitization to some of the effects of METH, such as psychosis that is often seen after repeated use of high METH doses.
There are three candidate mechanisms possibly mediating the inhibitory effects of fluoxetine on behaviors relating to METH dependence: (a) increase of basal extracellular serotonin concentration due to inhibition of SERT by fluoxetine, (b) blockade by fluoxetine of the actions of METH on SERT, and (c) actions of fluoxetine on molecules other than SERT. The first mechanism is supported by a report that inhibition of monoamine oxydase A, a major serotonin metabolizer, reduces METH-induced hyperlocomotion. 10 Secondly, the blockade of the actions of METH on the SERT by fluoxetine may reduce the toxicity induced by METH. METH induces reverse flow of dopamine and serotonin through DAT and SERT, respectively, and leads to toxicity after entering into the cytoplasm. 11 Thus, fluoxetine may protect the SERT from the actions of METH and thus reduces both the behavioral and toxic effects of METH. This second possibility is supported by reports that the METH-induced decrease in tryptophan hydroxylase activity is attenuated by fluoxetine. 12, 13 Finally, recent studies have shown that fluoxetine modulates the function of several ion channels and receptors, such as G protein-activated inwardly rectifying K + (GIRK) channels, 14 voltage-gated Ca 2+ , Na + and K + channels, [15] [16] [17] [18] [19] [20] [21] Cl − channels, 22 5-HT2C 23 and 5-HT3 receptors, 24 and nicotinic acetylcholine receptors. 25, 26 Thus, the actions of fluoxetine on these molecules, besides the actions on the SERT, may mediate the inhibitory effects of fluoxetine on METH dependence. Reduced cocaine self-administration in mice lacking the GIRK2 or GIRK3 subunit 27 supports this third possibility that fluoxetine inhibits METH dependence through inhibition of the GIRK channels.
In conclusion, we found that fluoxetine, a widely used medication for depression, inhibited both METH CPP and sensitization to METH-induced locomotor activation in mice. Although further preclinical studies are needed to elucidate the mechanisms underlying these inhibitory effects of fluoxetine on processed relating to METH dependence, it appears worthwhile to investigate the clinical effects of fluoxetine on METH abuse. The dopamine transporter (DAT) is the main target for METH and cocaine. However, mice lacking the DAT show conditioned place preference (CPP) to cocaine 4 and self-administer cocaine. 5 Interestingly, heterozygous and homozygous serotonin transporter (SERT) knockout mice that also have a homozygous knockout of the DAT do not exhibit cocaine CPP. 6 Cocaine administration leads to increases in extracellular dopamine concentration in the striatum of DAT knockout mice but not of DAT/SERT double knockout mice. 7 Taken together, these reports suggest that SERT inhibition may decrease METH and cocaine CPP.
Recently, we showed that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), abolished METH CPP when METH was administered during both the development and expression phases of the CPP procedure, supporting the hypothesis that SERT inhibition decreased the rewarding effects of METH. 8 To further test this hypothesis, in the present study we investigated the effects of the SSRIs paroxetine (Paxil 
MATERIALS AND METHODS
Mice
Male C57BL/6J mice (8-10 weeks old) were purchased from CLEA Japan, Inc. (Tokyo, Japan) and were housed for 1-2 weeks before the experiments began in an animal facility 
Conditioned Place Preference (CPP) Test
The CPP test was performed according to the method of Hoffman and Beninger 9 with some modifications. We used a two-compartment Plexiglas chamber (Neuroscience Inc., Osaka, Japan). One compartment (17.5 × 15 × 17.5 cm: width × length × height) was black with a smooth floor, and the other compartment was of the same dimensions, but with a white textured floor. This two-compartment chamber was located in a sound-and light-attenuated box under conditions of dim illumination (approximately 40 lux) to reduce bias toward either compartment. 10 Mice were assigned randomly to the treatment groups (see below).
On Day 1, the mice (n = 14-26 per group) were allowed to freely explore the two 
Drugs
Methamphetamine hydrochloride was purchased from Dainippon Pharmaceutical (Osaka, Japan). Paroxetine maleate and fluvoxamine maleate were purchased from Sigma (St.
Louis, MO, USA) and TOCRIS (Hung Road, Bristol, UK), respectively. All drugs were dissolved in saline. Drugs and vehicle were administered i.p. in a volume of 0.1 ml/10 g body weight. All drug doses are reported as salt.
Statistical Analyses
The CPP and transition scores of mice pretreated with saline or SSRI during the conditioning and CPP test phases were subjected to a two-way analysis of variance (ANOVA).
The ANOVA had two between-subjects factors, each with two levels (saline/SSRI pretreatment in the conditioning phase and saline/SSRI pretreatment in the CPP test phase). Two separate ANOVAs were conducted on the paroxetine and fluvoxamine data. Similar ANOVAs were conducted on the transition scores. The CPP scores from the paroxetine experiment were subjected to a one-way ANOVA followed by post hoc comparisons with the Scheffe test. In this ANOVA, there were four levels corresponding to the four treatment conditions (saline in both the conditioning and the CPP test phases, pretreatment with paroxetine only in the conditioning phase, pretreatment with paroxetine only in the CPP test phase, pretreatment with paroxetine in both the conditioning and the CPP test phases). For the CPP data, the durations of time that the mice spent in the METH-paired compartment before and after conditioning were compared using paired t-tests for each group. For the transition data, the number of transitions between the METH-paired compartment and the saline-paired compartment before and after conditioning were compared using paired t-tests for each group. The level of significance was set at 0.05.
RESULTS
Effects of Paroxetine on METH CPP
The two-way ANOVA revealed that mice treated with paroxetine during the test phase exhibited decreased CPP scores compared to mice treated with saline during the test phase (F 1,72 = 7.888, P < 0.01), whereas mice treated with paroxetine during the conditioning phase did not differ significantly from mice treated with saline during the test phase in the CPP score [F 1,72 = 1.704, not significant (n.s.) ; FIG. 1A ]. There was no statistically significant interaction between the factor saline/paroxetine during the conditioning phase and the factor saline/paroxetine during the CPP test phase (F 1,72 = 0.1690, n.s.), indicating that the important factor was treatment with paroxetine during the expression phase of the experiment. In addition, a one-way ANOVA on the CPP scores was conducted on data for all four groups. The ANOVA showed a significant difference in the CPP scores among these four groups (F 3,72 = 3.940, P < 0.05). The Scheffe post hoc test showed that the CPP score of the paroxetine/paroxetine group was significantly lower than that of the saline/saline group (P < 0.05). Paired t-tests were conducted to compare the duration of time before and after conditioning for each of the four groups (FIG. 1B) .
Whereas the saline/saline and paroxetine/saline groups spent significantly more time in the METH-paired compartment after conditioning than before conditioning (saline/saline: n = 23, df 8 = 22, t = -6.050, P < 0.001; paroxetine/saline: n = 15, df = 14, t = -2.884, P < 0.05), the saline/paroxetine and paroxetine/paroxetine groups did not show METH CPP (saline/paroxetine: n = 15, df = 14, t = -2.033, n.s.; paroxetine/paroxetine: n = 23, df = 22, t = -0.908, n.s.).
Paroxetine pretreatment had no significant effects on the transition scores compared to the saline/saline treatment group (data not shown).
Effects of Fluvoxamine on the METH CPP
The two-way ANOVA revealed that both the factor saline/fluvoxamine pretreatment during the conditioning phase and the factor saline/fluvoxamine pretreatment during the CPP test phase had no effects on CPP scores (conditioning phase: There was no statistically significant interaction between the two factors (F 1,68 = 0.007, n.s.).
Paired t-tests were conducted to compare the number of transitions before and after conditioning 9 for each of the four groups. The S-S group showed no significant differences in the number of transitions before and after conditioning (n = 26, df = 25, t = -1.213, n.s.). However, mice pretreated with fluvoxamine (saline/fluvoxamine, fluvoxamine/saline, fluvoxamine/fluvoxamine) showed significant decreases in the number of transitions after conditioning (saline/fluvoxamine: n = 14, df = 13, t = 3.829, P < 0.01; fluvoxamine/saline: n = 18, df = 17, t = 5.520, P < 0.001; fluvoxamine/fluvoxamine: n = 14, df = 13, t = 6.025, P < 0.001).
DISCUSSION
In the present study, we showed that paroxetine, a widely used medication for treating depression, inhibited METH CPP in mice, similar to the results we reported previously with fluoxetine. 8 No significant effects of paroxetine on transition scores suggest that the effects of paroxetine on METH CPP are not due to changes in locomotor activity but due to reduction of METH reward and conditioned reward by paroxetine. Based on these findings, it appears worthwhile to investigate the clinical effects of paroxetine on METH abuse. By contrast, the other SSRI tested here, fluvoxamine, did not affect METH CPP. These data demonstrate that there are differences in the effects of SSRIs on METH CPP, suggesting the possibility that molecules other than the SERT are involved in the inhibition of METH CPP by paroxetine and fluoxetine reported here and in our previous study. 8 In addition to SERT inhibition, paroxetine inhibits the function of muscarinic cholinergic receptors, 11 nicotinic acetylcholine receptors, 12 volume-related anion channels, 13 membrane steroid transporters, 14 and nitric oxide synthase. 15 Recently, Kobayashi and colleagues 16 reported that paroxetine also inhibits the function of G protein-activated inwardly 10 rectifying K + (GIRK) channels. It is intriguing that paroxetine and fluoxetine, but not fluvoxamine, inhibit GIRK channels. 16, 17, 18 Various G protein-coupled receptors (such as M2 muscarinic, α2 adrenergic, D 2 dopaminergic, 5-HT 1A , opioid, nociceptin/orphanin FQ, and A 1 adenosine) activate GIRK channels 19, 20, 21, 22 through the direct action of G protein subunits. 23 In addition, GIRK channels are activated by ethanol independently of G protein-coupled signaling pathways. 24, 25 Activation of GIRK channels leads to membrane hyperpolarization. 19 These channels play an important role in the inhibitory regulation of neuronal excitability.
Thus, modulators of GIRK channel activity may affect many brain functions. Kobayashi and colleagues 26 also have reported that ifenprodil, a cerebral vasodilator which inhibits morphine CPP, 27 also inhibits the function of GIRK channels. Morgan and colleagues 28 demonstrated that GIRK channel knockout mice exhibited dramatically reduced intravenous self-administration of cocaine. In the present study, we found that paroxetine and fluoxetine, but not fluvoxamine, inhibited METH CPP. These findings, together with the previous findings, suggest that the inhibition of GIRK channels by paroxetine or fluoxetine may be involved in the inhibition of METH CPP by these drugs.
Fluvoxamine administration (60 mg/kg) leads to a significant decrease in spontaneous locomotor activity. 29 Consistent with this observation, significant decreases in transition scores were observed in all of the 100 mg/kg fluvoxamine-treated groups compared to the saline/saline-treated group in the present study. The number of transitions of the fluvoxamine/fluvoxamine treated group during the CPP test phase (101.4 ± 85.3, mean ± SEM) was the smallest among the four groups in this experiment, but more than 100 transitions indicated adequate locomotion to reveal potential differences in CPP. The lack of effect of fluvoxamine on CPP for methamphetamine is likely to reflect a lack of effect of fluvoxamine on 11 the rewarding effects of METH rather than being a nonspecific effect of fluvoxamine.
CONCLUSION
We found that paroxetine, but not fluvoxamine, inhibited METH CPP in mice.
Although further preclinical studies are needed to elucidate the mechanisms underlying these inhibitory effects of paroxetine on processes relating to METH dependence, it appears worthwhile to investigate the clinical effects of paroxetine on METH abuse. The present results suggest that molecules other than the SERT (such as GIRK channels) are involved in the inhibition of METH CPP by paroxetine and fluoxetine. 
